Key result
First-line combined endo- and epicardial ventricular tachycardia ablation in patients with ARVD/C was associated with a 26.8% recurrence of VT and a 5% complication rate over 32.2 months.
Why the study?
Does a stepwise ablation approach (endocardial first) prevent unnecessary procedure-related complications compared to first-line combined endo-epicardial ablation in patients with ARVD/C and frequent VT?
Does a stepwise ablation approach (endocardial first) prevent unnecessary procedure-related complications compared to first-line combined endo-epicardial ablation in patients with ARVD/C and frequent VT?
A stepwise approach prioritizing endocardial ablation and reserving epicardial ablation for inducible VT may reduce complications associated with epicardial access in ARVD/C patients.
We read with great interest the recent manuscript of Berruezo and colleagues who reported the results of a prospective multicentre study on ‘safety, long-term outcomes and predictors of recurrence after first-line combined endoepicardial ventricular tachycardia substrate ablation in arrhythmogenic cardiomyopathy’.1 With an aggressive approach of first-line combined endo- and epicardial ventricular tachycardia (VT) ablation in 41 patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) the authors observed recurrences of VT in 11 patients (26.8%) after a mean follow-up of 32.2 + 21.8 months. Two patients (5%) suffered from procedure-related complications due to epicardial access, including one death.1 Other researchers sought for alternative ablation strategies. Komatsu et al. examined whether epicardial substrate ablation from the endocardium was feasible. Patients with different cardiomyopathies (ischaemic cardiomyopathy, non-ischaemic dilated cardiomyopathy, ARVD/C) and sustained VT underwent combined endo- and epicardial mapping. An at least partial elimination of epicardial substrate by endocardial ablation could be achieved in the majority of patients with ischaemic cardiomyopathy and ARVD/C but only in a small minority of patients with non-ischaemic dilated cardiomyopathy.2 Santangeli et al.3 reported good long-term outcomes in ARVD/C patients undergoing endocardial-only ablation, emphasizing that epicardial approach should be reserved for patients with inducible VT despite extensive endocardial ablation. We propose a stepwise approach with an endocardial ablation first and additional epicardial ablation only if VT are still inducible after thorough endocardial ablation. We have shown that endocardial ablation of VT seems to be sufficient to suppress VT inducibility in about half of patients with ARVD/C and frequent VT. Our inducibility-guided ablation strategy yielded similar long-term results after endocardial and after combined endo- and epicardial ablation and may therefore be a reasonable strategy to reduce complications due to unnecessary epicardial ablation.4 Further randomized studies are warranted to compare these two strategies.
No takes yet. Share an insight, caveat, or question.
Müssigbrodt et al. (2017) conducted a letter in Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) and frequent ventricular tachycardia (n=41). First-line combined endo- and epicardial ventricular tachycardia ablation was evaluated on Recurrences of ventricular tachycardia. First-line combined endo- and epicardial ventricular tachycardia ablation in patients with ARVD/C was associated with a 26.8% recurrence of VT and a 5% complication rate over 32.2 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: